Pharmacologic Management of Interstitial Cystitis/Bladder Pain Syndrome

Christopher J Chermansky; Marina O Guirguis

doi:10.1016/j.ucl.2022.01.003

Pharmacologic Management of Interstitial Cystitis/Bladder Pain Syndrome

Urol Clin North Am. 2022 May;49(2):273-282. doi: 10.1016/j.ucl.2022.01.003.

Authors

Christopher J Chermansky¹, Marina O Guirguis²

Affiliations

¹ Chief of Urology UPMC Magee Womens Hospital, 300 Halket Street, Suite 2541, Pittsburgh, PA 15213, USA. Electronic address: chermanskycj2@upmc.edu.
² Division of Urogynecology, Department of Obstetrics and Gynecology, Magee Womens Hospital, 300 Halket Street, Pittsburgh, PA 15213, USA. Electronic address: https://twitter.com/@MGuirguisMD.

PMID: 35428433
DOI: 10.1016/j.ucl.2022.01.003

Abstract

Interstitial cystitis/bladder pain syndrome (IC/BPS) is defined as persistent or chronic discomfort perceived to be related to the urinary bladder accompanied by urinary urgency or frequency. Pharmacotherapies used to treat IC/BPS include oral and intravesical agents. Oral therapies include amitriptyline, hydroxyzine, cyclosporine A, and pentosan polysulfate sodium (PPS), although the recent finding of pigmented maculopathy with chronic PPS is very concerning and must be discussed with patients, many of whom will choose to either come off this medicine or not even start it. Certolizumab pegol is a pharmacologic therapy that is currently in clinical development for treatment of IC/BPS symptoms.

Keywords: Bladder pain syndrome; Interstitial cystitis; Intravesical treatment; Pharmacology.

Publication types

Review

MeSH terms

Cystitis, Interstitial* / drug therapy
Female
Humans
Male
Pentosan Sulfuric Polyester / therapeutic use
Urinary Bladder

Substances

Pentosan Sulfuric Polyester